NeoGenomics, Inc. (NEO)

NeoGenomics beat expectations on revenue in the second fiscal quarter of 2026, reported July 28, 2026, with revenue up 11.2% to about $201.7 million (from roughly $181.3 million a year ago) as its cancer-focused testing and research services business continued to expand across Clinical Services and Pharma Services. On the consensus comparison, revenue of $201.7 million topped the $196.9 million estimate, +2.4%. Gross profit came in at about $91.9 million, translating to a gross margin of roughly 46%, while profitability remained negative at the operating line with operating income of about -$9.8 million and an operating margin of around -5%. Adjusted EPS was $0.05, up from $0.03 a year ago. The company generated operating cash flow of about $20.0 million during the quarter and repurchased roughly $22.7 million of stock. For the next period, consensus calls for EPS of $0.06 on revenue of $205.9 million.